What Makes the Regenexx Same Day Procedure Different?

We’ve been pioneering this field of stem cells used to treat orthopedic problems since 2005. In that time, we’ve made several advancements to keep us way ahead of the pack. One of those advancements is our unique way of processing bone marrow aspirate for our Regenexx Same Day Stem Cell Procedure.

What is a bone marrow aspirate? The link will explain this in detail.

Almost all physicians who use bone marrow concentrate (a same day stem cell injection procedure) utilize automated bedside centrifuges to process the bone marrow aspirate (BMA) sample. The goal of this processing is to concentrate the stem cell containing fraction of the aspirate. The resulting mix of cells of that process is called “bone marrow concentrate” (BMC).

All automated machines use the same basic process to concentrate BMC—they capture the “buffy coat” with varying levels of efficiency. The buffy coat is a small, gray in color, middle layer that appears after the BMC has been centrifuged. Given changes in each patient’s hydration and hematocrit levels, it’s not hard to see that this layer may appear at differing heights in different patients.

Most of the automated bedside machines in use today account for this inter-patient variation by taking a large cut of sample above and below the buffy coat, reducing the total BMA volume from 60 cc to approximately 10 cc. Given that the size of the buffy coat in a 60 ml sample is usually 1–2 cc, this creates a concentration problem (i.e., 1–2 cc of active ingredient diluted in 10 cc). When the Regenexx group medical practice first began, our focus was also on capturing this layer. However, manually processing this layer in a laminar flow hood in a medical practice resulted in much higher concentrations, as the usual dilution we could accomplish was 1–2 ml of active buffy coat in approximately 3 ml of total BMC. Hence, what all that means is that the first version of our process was more advanced than automated bedside units because it produced an injectate with 3–4 times the concentration of the buffy coat active ingredient, over automated bedside systems.

In 2012, our group medical practice asked the question of whether it was possible to increase mesenchymal stem cell (MSC) levels even higher. We were able to find a second source of MSCs in Bone Marrow Aspirate that was being discarded. This is a proprietary discovery that is the subject of a patent application, so I will describe it with that in mind.

The chart entitled “P0 Counts” is a comparison of the MSC content of the two layers with the traditional buffy-coat (BC) isolation versus the new source (we call this LLD). As you can see, the differences in the number of MSCs obtained via colony formation after plating the buffy coat versus the LLD is stark. In all 7 patients tested, LLD MSC content significantly beats the buffy coat.

In addition, other studies performed in our Regenexx lab found that the MSCs in the LLD were faster growing and more chondrogenic (more capable of cartilage repair) than those found in the buffy coat. For example, the graph entitled “Day 8 mRNA Levels” shows that the gene-expression panel associated with chondrogenesis is hugely upregulated in LLD cells, versus buffy-coat cells.

When we added these two fractions together, we were now producing a BMC that had an MSC content that was reliably 5–7 times higher than what could be obtained via automated bedside centrifuges. In addition, given the orthopedic injury focus of the group medical practice, the fact that MSCs from the LLD are present is very important to us. However, we also sought additional validation that this new processing technique would translate into better clinical success. The graph entitled “Second Generation Regenexx-SD Procedure” represents a prospective registry comparison trial between the first-generation processing and the newer second-generation technique (BC+LLD). In treating knee osteoarthritis patients, the Lower Extremity Functional Scale (LEFS, functional improvement), Numeric Pain Rating Scale (NPRS, pain improvement), and self-reported percentage of improvement were all significantly better with an injection of the new processing technique containing more MSCs.

The upshot? What we do at Regenexx can’t be replicated by the doctors using bedside machines for processing your bone marrow. It’s unique!

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

Get Blog Updates by Email

First Name *

Last Name *

Email *

Which Blog Would You Like To Subscribe To?

Please select one *Daily BlogWeekly Blog

Subscribe

We do not sell, or share your information to third party vendors.

By submitting the form you agree that you’ve read and consent to our Privacy Policy. We may use email, phone, or other electronic means to communicate information about Regenexx.

We will provide information to help you decide whether you want to schedule an evaluation with a Regenexx Physician.

Insurance typically covers evaluations and diagnostic testing (if recommended). Most insurance plans currently do not cover Regenexx Procedures.